Literature DB >> 7533152

Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.

T Hüsler1, D H Lockert, K M Kaufman, J M Sodetz, P J Sims.   

Abstract

CD59 antigen is a membrane glycoprotein that inhibits the activity of the C9 component of the C5b-9 membrane attack complex, thereby protecting human cells from lysis by human complement. The complement-inhibitory activity of CD59 is species-selective and is most effective toward C9 derived from human or other primate plasma. By contrast, rabbit C9, which can substitute for human C9 in the membrane attack complex, mediates unrestricted lysis of human cells. To identify the peptide segment of human C9 that is recognized by CD59, rabbit C9 cDNA clones were isolated, characterized, and used to construct hybrid cDNAs for expression of full-length human/rabbit C9 chimeras in COS-7 cells. All resulting chimeras were hemolytically active, when tested against chicken erythrocytes bearing C5b-8 complexes. Assays performed in the presence or absence of CD59 revealed that this inhibitor reduced the hemolytic activity of those chimeras containing human C9 sequence between residues 334-415, irrespective of whether the remainder of the protein contained human or rabbit sequence. By contrast, when this segment of C9 contained rabbit sequence, lytic activity was unaffected by CD59. These data establish that human C9 residues 334-415 contain the site recognized by CD59, and they suggest that sequence variability within this segment of C9 is responsible for the observed species-selective inhibitory activity of CD59.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533152     DOI: 10.1074/jbc.270.8.3483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Membrane assembly of the cholesterol-dependent cytolysin pore complex.

Authors:  Eileen M Hotze; Rodney K Tweten
Journal:  Biochim Biophys Acta       Date:  2011-07-31

2.  Binding of human and rat CD59 to the terminal complement complexes.

Authors:  T Lehto; B P Morgan; S Meri
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

3.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

4.  Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.

Authors:  N K Rushmere; S Tomlinson; B P Morgan
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 5.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

6.  Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab.

Authors:  Katharina Stadlbauer; Peter Andorfer; Gerhard Stadlmayr; Florian Rüker; Gordana Wozniak-Knopp
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

Review 7.  Complement activation: an emerging player in the pathogenesis of cardiovascular disease.

Authors:  Angela M Carter
Journal:  Scientifica (Cairo)       Date:  2012-12-16

Review 8.  Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine.

Authors:  Andrea Maugeri; Martina Barchitta; Maria Grazia Mazzone; Francesco Giuliano; Antonella Agodi
Journal:  Biomed Res Int       Date:  2018-08-26       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.